Product Reports Resources Pricing Login Book a demo

Osivax

Biotech & Life Sciences · Lyon, France · Founded 2017

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM™, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 volunteers tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide. For further information: www.osivax.com

Valuation $0–100M
Revenue <$1M
Headcount <100
Total funding $50–100M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Osivax and the history behind them.

Investors

9 investors on Osivax's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 5 investors entered at this stage
European Innovation Council
Bpifrance
Bill & Melinda Gates Foundation
US National Institute of Allergy and Infectious Diseases
US Biomedical Advanced Research and Development Authority
Series A 4 investors entered at this stage
Noshaq
Anaxago
EIC Fund
Meiji Seika Pharma

Global footprint

Where Osivax has talent and traffic

Workforce by country
4 countries with
team presence
🇫🇷 France72.7%
🇧🇪 Belgium23.6%
🇱🇺 Luxembourg1.8%
🇨🇭 Switzerland1.8%
4 countries shown

Talent graph

The shape of Osivax's talent

Dealroom maps Osivax's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 team members profilednamed & role-tagged by Dealroom
60 employeestotal headcount
3 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Osivax's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Osivax

An AI-synthesized read of the highest-engagement posts about Osivax on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Osivax on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles